Abstract
• Gastric-type endocervical adenocarcinomas (GEA) are rare, aggressive cancers with limited therapeutic options. • Although therapeutic effects of PARP-inhibitors in non-BRCA-associated cancers might be limited, clinical data is sparse. • Given limited treatment options and poor prognosis of GEA, somatic BRCA mutation testing, and PARP-inhibitor maintenance can be considered.